| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Enoblituzumab (anti-CD276)
CAS:1353485-38-7
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:5mg Remarks:K10774
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Enoblituzumab
CAS:1353485-38-7
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Enoblituzumab
CAS:1353485-38-7
Purity:95% Package:1mg;1g;100g
|
MGA271 manufacturers
- Enoblituzumab
-
- $195.00 / 1mg
-
2025-09-11
- CAS:1353485-38-7
- Min. Order:
- Purity: 96.7% (SDS-PAGE); 98.5% (SEC-HPLC)
- Supply Ability: 10g
|
| Product Name: | MGA271 | | Synonyms: | MGA271;Enoblituzumab;Research Grade Enoblituzumab(DHJ04001);Enoblituzumab (anti-CD276);MGA271|||TJ-271;Research Grade Enoblituzumab | | CAS: | 1353485-38-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![MGA271 Structure]() |
| | MGA271 Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | MGA271 Usage And Synthesis |
| Uses | Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators[1]. | | in vivo | Enoblituzumab (5 mg/kg; i.v.; single dose) exhibits estimated half-life of 249 hours with a Cmax of 43 mg/mL in mice (mCD16-/-hCD16A+) that murine CD16 gene knocked out and are transgenic for human CD16A-158F[3].
Enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) exhibits potent antitumor activity in B7-H3-expressing xenograft mice models of renal cell and bladder carcinoma[3].
| Animal Model: | mCD16-/-hCD16A+ mice implanted with A498 renal cell carcinoma, 786-0 renal cell carcinoma, or HT-1197 bladder carcinoma cells (s.c.)[3] | | Dosage: | 1 mg/kg, 5 mg/kg, 10 mg/kg | | Administration: | Intravenous injection; once weekly; 5 weeks | | Result: | Significantly inhibited tumor growth at doses of 1 mg/kg or greater with once weekly treatment.
Achieved a cytostatic response at 5 or 10 mg/kg until day 52, after which the average tumor volume of the 5 mg/kg treatment group remained near predose administration levels, whereas a nonsignificant trend toward relapse exhibited in the 10 mg/kg group. |
| | References | [1] Hińcza-Nowak K, et al. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy. Genes (Basel). 2021 Sep 28;12(10):1534. DOI:10.3390/genes12101534
[2] Chapoval, et al. Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors. Russ J Bioorg Chem 45, 321–334 (2019).
[3] Loo D, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3834-45. DOI:10.1158/1078-0432.CCR-12-0715 |
| | MGA271 Preparation Products And Raw materials |
|